A compound of formula wherein R 1 and R 4 may be the same or different and are independently selected from the group consisting of: H, (C 3 -C 7) cycloalkyl and aryl, said aryl being optionally and independently substituted by one or more groups selected from halogen, -OH, (C 1 -C 6) alkyl, (C 1 -C 6) haloalkyl and (C 1 -C 6) hydroxyalkyl; R 2 is H or (C 1 -C 6) alkyl; R 3 is H; R 5 is selected from the group consisting of: -NR 6 R 7, (C 1 -C 6) alkyl, (C 1 -C 6) haloalkyl, (C 1 -C 6) hydroxyalkyl, (C 1 -C 6) aminoalkyl, (C 3 -C 7) cycloalkyl, aryl, heteroaryl, and heterocycloalkyl; said aryl, heteroaryl, and heterocycloalkyl being optionally and independently substituted by one or more groups selected from halogen, -OH, -CN, (C 1 -C 6) alkyl; Cy is a heteroaryl selected from the group consisting of 9H-purin-6-yl (I-3), 1H-pyrazolo[3,4-d]pyrimidin-1-yl, (I-4), pyrimidin-4-yl (I-6),; said heteroaryl can be optionally and independently substituted by one or more groups selected from halogen,-OH, -(CH 2) p NR 6 R 7; -CN, (C 1 -C 6) alkyl, (C 1 -C 6) haloalkyl, (C 1 -C 6) hydroxyalkyl, and aryl, said aryl can be optionally and independently substituted with one or more groups selected from -OH, halogen, -CN, (C 1 -C 6) alkyl, (C 1 -C 6) haloalkyl, (C 1 -C 6) hydroxyalkyl; R 6, R 7 may have the same or different meanings at each occurrence, and are independently selected from the group consisting of -H and (C 1 -C 6) alkyl, (C 1 -C 6) haloalkyl, (C 1 -C 6) hydroxyalkyl, or they form, taken together with a nitrogen atom they are linked to, a 4 to 6 membered heterocycle optionally containing one or more additional group selected from O, S, N, NH; Z, when present, is -NH;m is zero or 1; n is 1 or 2; p at each occurrence independently is zero or an integer ranging from 1 to 3; or pharmaceutically acceptable salts and or solvates thereof; wherein said aryl are mono, bi- or tri-cyclic carbon ring systems which have 6 to 20 atoms, wherein at least one ring is aromatic; said heteroaryl are mono-, bi- or tri-cyclic ring systems with 5 to 20 atoms, in which at least one ring is aromatic and in which at least one ring atom is a group selected from N, NH, S or O; said heterocycloalkyl refers to saturated or partially unsaturated monocyclic cycloalkyl groups, which have 3 to 6 ring atoms, in which at least one ring carbon atom is replaced by at least one group selected from N, NH, S or O. R 1 and R 4 may be the same or different and are independently selected from the group consisting of: H, (C 3 -C 7) cycloalkyl and aryl, said aryl being optionally and independently substituted by one or more groups selected from halogen, -OH, (C 1 -C 6) alkyl, (C 1 -C 6) haloalkyl and (C 1 -C 6) hydroxyalkyl; R 2 is H or (C 1 -C 6) alkyl; R 3 is H; R 5 is selected from the group consisting of: -NR 6 R 7, (C 1 -C 6) alkyl, (C 1 -C 6) haloalkyl, (C 1 -C 6) hydroxyalkyl, (C 1 -C 6) aminoalkyl, (C 3 -C 7) cycloalkyl, aryl, heteroaryl, and heterocycloalkyl; said aryl, heteroaryl, and heterocycloalkyl being optionally and independently substituted by one or more groups selected from halogen, -OH, -CN, (C 1 -C 6) alkyl; Cy is a heteroaryl selected from the group consisting of 9H-purin-6-yl (I-3), 1H-pyrazolo[3,4-d]pyrimidin-1-yl, (I-4), pyrimidin-4-yl (I-6),; said heteroaryl can be optionally and independently substituted by one or more groups selected from halogen,-OH, -(CH 2) p NR 6 R 7; -CN, (C 1 -C 6) alkyl, (C 1 -C 6) haloalkyl, (C 1 -C 6) hydroxyalkyl, and aryl, said aryl can be optionally and independently substituted with one or more groups selected from -OH, halogen, -CN, (C 1 -C 6) alkyl, (C 1 -C 6) haloalkyl, (C 1 -C 6) hydroxyalkyl; R 6, R 7 may have the same or different meanings at each occurrence, and are independently selected from the group consisting of -H and (C 1 -C 6) alkyl, (C 1 -C 6) haloalkyl, (C 1 -C 6) hydroxyalkyl, or they form, taken together with a nitrogen atom they are linked to, a 4 to 6 membered heterocycle optionally containing one or more additional group selected from O, S, N, NH; Z, when present, is -NH;m is zero or 1; n is 1 or 2; p at each occurrence independently is zero or an integer ranging from 1 to 3; or pharmaceutically acceptable salts and or solvates thereof; wherein said aryl are mono, bi- or tri-cyclic carbon ring systems which have 6 to 20 atoms, wherein at least one ring is aromatic; said heteroaryl are mono-, bi- or tri-cyclic ring systems with 5 to 20 atoms, in which at least one ring is aromatic and in which at least one ring atom is a group selected from N, NH, S or O; said heterocycloalkyl refers to saturated or partially unsaturated monocyclic cycloalkyl groups, which have 3 to 6 ring atoms, in which at least one ring carbon atom is replaced by at least one group selected from N, NH, S or O.